DYN · Dyne Therapeutics Inc
United States · RS rating 46 · As of 2026-11-03
| Price | 18.05 USD |
|---|---|
| 1-day change | +4.3% |
| RS rating (overall / 1M / 3M / 12M) | 46 / 91 / 20 / 36 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 28 / 12 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +32.6% |
| Market cap (USD) | $3.1B |